In contrast to standard monoclonal antibodies, bispecific antibodies are engineered to bind two distinct targets simultaneously.
Bispecific antibodies perform special functions
This capability enables them to perform special functions like bringing two different molecules together or binding two sites on the same protein.
Antiviral bispecific antibodies benefit from these special functions
In the case of antiviral bispecific antibodies, the ability to target two distinct sites has important consequences; it can increase the likelihood that the bispecific antibody will retain antiviral activity despite changes to the virus. This is a similar concept to the use of a ‘cocktail’ of two different monoclonal antibodies, but can be achieved with a single bispecific antibody.
And potently inhibit SARS-CoV-2, the virus that causes COVID-19
To address the emergence of new variants of SARS-CoV-2, the virus that causes COVID-19, RenBio is developing a novel bispecific antibody that targets both the receptor binding domain (RBD) and N-terminal domain (NTD) of the SARS-CoV-2 spike protein, thereby significantly reducing the ability of the virus to infect cells.